Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.
about
Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentanOptimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment courseEndothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.Macitentan for the treatment of pulmonary arterial hypertension.Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide.Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future.Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.Macitentan: first global approval.Macitentan: a review of its use in patients with pulmonary arterial hypertension.Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.New pharmacotherapy options for pulmonary arterial hypertension.Development of macitentan for the treatment of pulmonary arterial hypertension.Macitentan: A Review in Pulmonary Arterial Hypertension.Macitentan: An important addition to the treatment of pulmonary arterial hypertension.Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.Macitentan in pulmonary arterial hypertension: The SERAPHIN trialInvestigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.Lack of Pharmacokinetic Interactions Between Macitentan and a Combined Oral Contraceptive in Healthy Female Subjects.Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects.Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
P2860
Q26851546-F3F49EAD-B220-4219-8EFC-494186210439Q27023074-B0626F42-3B3E-4801-9DDF-1F8E36ADDF72Q28246158-F75ED5AF-93DA-4BA5-8CA2-E72397A91CB3Q34570893-7CDCD5FA-22A6-4F7C-A84B-4260BDFE3CD2Q34610092-30135DF6-442F-4C94-B3EC-F7DC031A9349Q37207803-A17714E7-B4F7-48D5-B340-4CA7B5E12DC6Q37534587-93133958-19B0-4054-9441-BF088F2187E2Q38077796-182D4F76-5B3B-4F32-8561-AA028542EB40Q38164816-E49D7374-9A31-4D6B-ACD6-E43134FA0AC6Q38168144-4D41EC77-37A7-45CC-9D14-052172D704E7Q38233833-F3C5F4AB-EC06-4222-80D0-F7C715C4B257Q38271119-E8E4D4DC-5211-4565-84D2-5D440EBE51D5Q38325919-3522A059-F93C-4C31-A8A2-EBC82BBF3F20Q38569940-9F365964-5EEF-4034-B781-2FE438DBA594Q38570060-71C9853C-7199-43CB-9803-F36C9C58AC8EQ38942648-A1CD7594-1889-4D8E-A4C9-32290CADC906Q40259209-A50C81C3-C10B-4A84-9B9E-669A3F80B4EFQ40991626-FB4CEA3D-0CA9-412E-8659-BB170BF91A7AQ41773926-53D38F09-2878-48A3-A7E6-7A55AAF9BDB3Q43576010-B02843E9-6D96-47FD-9E3C-9C106343C21DQ44607924-204148EF-85BC-47DA-8C7F-D435F4392454Q47895451-1CF7258E-C17A-4BB6-A2D4-21FD64A52399Q50854224-479D9BB0-63F1-48E1-923B-114792A69DC1Q50982502-9DC00A68-2B5E-4AA6-82DA-CDA5AFB6E18FQ53089410-7930B0AE-CE6D-4543-9F2B-FF34A11C5FB4Q57484162-2E2E45F8-DBF3-45B7-8A0F-9D2271E76308
P2860
Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effect of cyclosporine and rif ...... ndothelin receptor antagonist.
@ast
Effect of cyclosporine and rif ...... ndothelin receptor antagonist.
@en
Effect of cyclosporine and rif ...... ndothelin receptor antagonist.
@nl
type
label
Effect of cyclosporine and rif ...... ndothelin receptor antagonist.
@ast
Effect of cyclosporine and rif ...... ndothelin receptor antagonist.
@en
Effect of cyclosporine and rif ...... ndothelin receptor antagonist.
@nl
prefLabel
Effect of cyclosporine and rif ...... ndothelin receptor antagonist.
@ast
Effect of cyclosporine and rif ...... ndothelin receptor antagonist.
@en
Effect of cyclosporine and rif ...... ndothelin receptor antagonist.
@nl
P2093
P2860
P1433
P1476
Effect of cyclosporine and rif ...... ndothelin receptor antagonist.
@en
P2093
Alexander Treiber
Jasper Dingemanse
Kyle Landskroner
Marie-Claude Homery
Patricia N Sidharta
Päivi Aänismaa
Shirin Bruderer
Stephanie Häusler
P2860
P2888
P356
10.1208/S12248-011-9316-3
P407
P577
2011-12-22T00:00:00Z
P5875
P6179
1029649104